Detailed information for compound 66704

Basic information

Technical information
  • TDR Targets ID: 66704
  • Name: (2-cyclohexyl-6-hydroxy-1-benzothiophen-3-yl) -[4-(2-piperidin-1-ylethoxy)phenyl]methanone
  • MW: 463.632 | Formula: C28H33NO3S
  • H donors: 1 H acceptors: 2 LogP: 6.98 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)C1CCCCC1
  • InChi: 1S/C28H33NO3S/c30-22-11-14-24-25(19-22)33-28(21-7-3-1-4-8-21)26(24)27(31)20-9-12-23(13-10-20)32-18-17-29-15-5-2-6-16-29/h9-14,19,21,30H,1-8,15-18H2
  • InChiKey: IZGMIMKTZXSTLH-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (2-cyclohexyl-6-hydroxy-benzothiophen-3-yl)-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone
  • (2-cyclohexyl-6-hydroxy-3-benzothiophenyl)-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone
  • (2-cyclohexyl-6-hydroxy-benzothiophen-3-yl)-[4-(2-piperidinoethoxy)phenyl]methanone
  • (2-cyclohexy-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1- piperidinyl)ethoxy)phenyl) methanone hydrochloride

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens estrogen receptor 2 (ER beta) References
Homo sapiens estrogen receptor 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Loa Loa (eye worm) hypothetical protein estrogen receptor 2 (ER beta) 495 aa 418 aa 25.8 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Mycobacterium ulcerans histidinol dehydrogenase 1.275 0.5 0.5
Mycobacterium tuberculosis Probable histidinol dehydrogenase HisD (HDH) 1.275 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) Tissue specific estrogen agonist effect in an ovariectomized rat model utilizing uterine eosinophil peroxidase activity : Not significant ChEMBL. No reference
Activity (functional) Effect on uterine weight as tissue specific estrogen agonist assay in ovariectomized rat model: significant increase at <=10 mg/kg dose ChEMBL. No reference
Activity (functional) 0 Effect on uterine weight as tissue specific estrogen agonist assay in ovariectomized rat model: significant increase at <=10 mg/kg dose ChEMBL. No reference
Activity (functional) 0 Tissue specific estrogen agonist effect in an ovariectomized rat model utilizing uterine eosinophil peroxidase activity : Not significant ChEMBL. No reference
Decrease (functional) = -0.1 % Percent decrease in serum cholesterol relative to OVX control at 0.1 mg/kg in rats ChEMBL. 9003514
Decrease (functional) = 52.9 % Percent decrease in serum cholesterol relative to OVX control at 1.0 mg/kg in rats ChEMBL. 9003514
Decrease (functional) = 61.7 % Percent decrease in serum cholesterol relative to OVX control at 10 mg/kg in rat was determined (in vivo) ChEMBL. 9003514
Dose (functional) = 2.5 nM Inhibition of MCF-7 cell proliferation stimulated by 10e-12 M estradiol ChEMBL. No reference
Dose (functional) = 2.5 nM Inhibition of MCF-7 cell proliferation stimulated by 10e-12 M estradiol ChEMBL. No reference
ED50 (functional) = 2.1 mg kg-1 Dose required to reduce serum cholesterol by 50% relative to OVX controls was determined (in vivo) ChEMBL. 9003514
Efficacy (functional) = 1.2 % Tissue specific estrogen agonist effect in an ovariectomized rat model utilizing serum cholesterol levels as end points ChEMBL. No reference
Efficacy (functional) = 1.2 % Tissue specific estrogen agonist effect in an ovariectomized rat model utilizing serum cholesterol levels as end points ChEMBL. No reference
IC50 (functional) = 2.5 nM Antagonism of estrogen action in a mammary tumor cell line was assayed via inhibition of MCF-7 cell proliferation stimulated by 10 e-11 M 17-beta-estradiol (in vitro) ChEMBL. 9003514
IC50 (functional) = 2.5 nM Antagonism of estrogen action in a mammary tumor cell line was assayed via inhibition of MCF-7 cell proliferation stimulated by 10 e-11 M 17-beta-estradiol (in vitro) ChEMBL. 9003514
Increase (functional) = 30.2 % Minimum effective dose at which significant increase in uterine weight/body weight in rat was determined (in vivo); expressed as % increase relative to ovariectomized (OVX) controls ChEMBL. 9003514
MED (functional) = 1 mg kg-1 Minimum effective dose at which significant increase in uterine weight/body weight in rat was determined (in vivo) ChEMBL. 9003514
MED (functional) > 10 mg kg-1 Minimum effective dose at which significant increase in uterine eosinophil peroxidase (EPO) activity in rat was determined (in vivo) ChEMBL. 9003514
RBA (binding) = 0.09 In vitro relative binding affinity by competition with [3H]-17-beta-estradiol for estrogen receptor in MCF-7 cell lysate ChEMBL. 9003514
RBA (binding) = 0.09 Binding affinity against estrogen receptor relative to [3H]-estradiol ChEMBL. No reference
RBA (functional) = 2.19 Displacement of tritiated [3H]-raloxifene binding in MCF-7 cell lysate ChEMBL. No reference
RBA (binding) = 0.09 Binding affinity against estrogen receptor relative to [3H]-estradiol ChEMBL. No reference
RBA (binding) = 0.09 In vitro relative binding affinity by competition with [3H]-17-beta-estradiol for estrogen receptor in MCF-7 cell lysate ChEMBL. 9003514
RBA (functional) = 2.19 Displacement of tritiated [3H]-raloxifene binding in MCF-7 cell lysate ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.